Michael Sarosdy - Concepedia

Concepedia

Author

Michael Sarosdy

The University of Texas at San Antonio

Also Known As

M Sarosdy, M. Sarosdy, Michael E. Sarosdy, Michael Sarosdy, Urs Schmutz

17

Publications

1.7K

Citations

10

H-Index

10

Concepts

All Affiliations

The University of Texas at San Antonio The University of Texas Health Science Center at San Antonio University of Colorado Denver Dana-Farber Cancer Institute Eastern Virginia Medical School

MS

About

Michael Sarosdy is an author at The University of Texas at San Antonio specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	213
2	Pharmacology	2	2	164
3	Cancer Therapeutics	2	2	164
4	Surgical Oncology	1	1	20
5	Brachytherapy	1	1	20

Michael Sarosdy

×

10

Publications

1.7K

Citations

10

H-Index

	Year	Citations
Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer Edward M. Messing, Judith Manola, Michael Sarosdy, New England Journal of Medicine	1999	1.2K
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer Paul F. Schellhammer, Anthony L. Patterson, Roohollah Sharifi, Urology UrologyOncologyHormone Analogue TherapyControlled TrialMedicine	1995	123
Genetic pattern of prostate cancer progression Tomo Šarić, Zoran Brkanac, Dean A. Troyer, International Journal of Cancer	1999	83
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. Han Xiao, Madhu Mazumdar, Dean F. Bajorin, Journal of Clinical Oncology	1997	82
Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886 Edward M. Messing, Judith Manola, Michael Sarosdy, Journal of Clinical Oncology	2004	48
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy Paul F. Schellhammer, Roohollah Sharifi, Norman L. Block, Urology UrologyOncologyHormone Analogue TherapyMaximal Androgen BlockadeMedicine	1996	41
Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer Augustin J. Suarez, Donald L. Lamm, Howard M. Radwin, Cancer Chemotherapy and Pharmacology UrologyGenitourinary CancerMedicineAndrogen PrimingProstatic Disease	1982	29
A Controlled Trial of Casodex™(Bicalutamide) vs. Flutamide,Each in Combination with LuteinisingHormone-Releasing HormoneAnalogue Therapy in Patients withAdvanced Prostate Cancer Mark S. Soloway, Paul F. Schellhammer, ROOHOLIAH SHARIFI, European Urology	1996	23
IMMEDIATE HORMONAL THERAPY VS. OBSERVATION FOR NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY AND PELVIC LYMPHADENECTOMY Edward M. Messing, Judith Manola, George Wilding, The Journal of Urology Surgical OncologyUrologyGenitourinary CancerMedicineBrachytherapy	1999	20
High-dose versus low-dose intravesical interferon-α2b in the treatment of carcinoma in situ Michael Sarosdy Anti-Cancer Drugs	1992	12

Page 1